Page 2 - Nasdaq Atha News Today

Athira Pharma (NASDAQ:ATHA – Get Rating) is scheduled to post its quarterly earnings results on Wednesday, May 10th. Athira Pharma Trading Down 3.4 % ATHA opened at $2.86 on Tuesday. Athira Pharma has a 1-year low of $2.22 and a 1-year high of $9.92. The stock has a market capitalization of $108.51 million, a price-to-earnings […]

Athira Pharma (NASDAQ:ATHA – Get Rating) and Exelixis (NASDAQ:EXEL – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership. Institutional and Insider Ownership 58.7% of Athira Pharma shares are held […]

Athira Pharma (NASDAQ:ATHA – Get Rating) and Exelixis (NASDAQ:EXEL – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Volatility & Risk Athira Pharma has a beta of 2.82, suggesting […]

Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 2,440,000 shares, an increase of 8.4% from the March 15th total of 2,250,000 shares. Approximately 6.8% of the company’s stock are short sold. Based on an average […]

Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,250,000 shares, an increase of 9.8% from the February 28th total of 2,050,000 shares. Based on an average daily trading volume, of 328,000 shares, the days-to-cover ratio […]

Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) Director James A. Johnson bought 5,000 shares of Athira Pharma stock in a transaction on Wednesday, March 29th. The shares were purchased at an average cost of $2.40 per share, with a total value of $12,000.00. Following the acquisition, the director now directly owns 5,000 shares of the […]

Data highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF/MET system...

SG Americas Securities LLC bought a new stake in Athira Pharma, Inc. (NASDAQ:ATHA – Get Rating) during the 2nd quarter, Holdings Channel.com reports. The fund bought 12,504 shares of the company’s stock, valued at approximately $38,000. Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Nisa […]

Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of...

BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...